Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial
published in: Lancet Neurology
date of publication: 2020-10-29
main subject: primary progressive multiple sclerosis
Cites articles
There is nothing here
Article - wd:Q101137154